Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.45 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on their clinical development despite the lack of specific guidance. They emphasized the significance of their ongoing trials.
Management expressed a commitment to advancing their clinical programs.
They noted the importance of upcoming trials in shaping future results.
Madrigal Pharmaceuticals reported a loss of $0.45 per share, which was in line with expectations, but no revenue figures were disclosed. The stock reacted negatively, dropping 1.0%, likely due to the absence of revenue data and guidance. Investors may be cautious as the company continues to navigate its clinical trials without clear financial direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NUTRIEN LTD
May 7, 2018